Cephalon Inc has completed its previously announced acquisition of all of the outstanding shares of Cima Labs Inc. As a result of the acquisition, Cima is now a wholly owned subsidiary of Cephalon.
Founded in 1987, Cephalon Inc is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products to treat sleep and neurological disorders, cancer and pain.
The company currently markets three proprietary products in the United States: Provigil (modafinil) [C-IV], Gabitril (tiagabine hydrochloride) and Actiq (oral transmucosal fentanyl citrate) [C-II] and more than 20 products internationally.